Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

baxter medical ab - ifosfamid - infusionsvätska, lösning - 40 mg/ml - ifosfamid 40 mg aktiv substans - ifosfamid

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - ifosfamid - pulver till injektions-/infusionsvätska, lösning - ifosfamid 1 mg aktiv substans

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - ifosfamid - pulver till injektions-/infusionsvätska, lösning - ifosfamid 1 mg aktiv substans

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - cyklofosfamidmonohydrat - pulver till injektions-/infusionsvätska, lösning - 500 mg - cyklofosfamidmonohydrat 534 mg aktiv substans; mannitol hjälpämne

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - cyklofosfamidmonohydrat - pulver till injektions-/infusionsvätska, lösning - 1000 mg - mannitol hjälpämne; cyklofosfamidmonohydrat 1069 mg aktiv substans

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfom, follikel - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiska medel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiska medel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.